Catalyst Pharmaceuticals Inc (CPRX) Stock
CPRX is no longer traded. Catalyst Pharmaceuticals was acquired by Angelini Pharma in July 2026.
Each CPRX share was exchanged for $31.50 in cash. Prices on this page are historical; the last trade was July 14, 2026 at $31.49.
Catalyst Pharmaceuticals stock price history
CPRX final trading statistics
- Final close
- $31.49
- Final trading day
- Jul 14, 2026
- Market cap at delisting
- $3.85B
- Shares outstanding
- 122.42M
- Final 52-week range
- $19.05 – $32.56
- Avg. volume (final 3 mo.)
- 2,639,644
- All-time high (split-adj.)
- $31.50 · Jun 2026
- All-time low (split-adj.)
- $0.39 · Nov 2012
- Return since IPO
- +416.2%
- Beta
- 0.74
- Book value / share
- $8.29
- Price / book
- 3.80
Catalyst Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $588.99M | $214.3M | $2.45 |
| FY2024 | $491.73M | $163.9M | $1.95 |
| FY2023 | $398.20M | $71.4M | $0.61 |
| FY2022 | $214.20M | $83.1M | $0.78 |
| FY2021 | $140.83M | $39.5M | $0.37 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals stock FAQ
What happened to Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals was acquired by Angelini Pharma in July 2026. Shareholders received $31.50 in cash for each share. CPRX stock stopped trading on the Nasdaq, with a final close of $31.49 on July 14, 2026.
What did Catalyst Pharmaceuticals shareholders receive?
Each CPRX share was converted into $31.50 in cash.
Is CPRX stock still trading?
No. CPRX was delisted from the Nasdaq in July 2026 and no longer trades on a U.S. exchange.
What was the last price of CPRX stock?
CPRX closed at $31.49 on its final trading day, July 14, 2026, for a market value of about $3.85B.
What were Catalyst Pharmaceuticals's revenue and earnings in its last full fiscal year?
Catalyst Pharmaceuticals reported revenue of $588.99M and net income of $214.3M in fiscal 2025, its last full year as a public company.
When did Catalyst Pharmaceuticals go public?
Catalyst Pharmaceuticals Inc stock began trading on November 8, 2006.